NTT-ELECTRONICS
NTT Electronics Corporation, a leading supplier of coherent Digital Signal Processor (DSP) solutions to system and module manufacturers worldwide, today announced addition of a low power consumption 400G Coherent DSP to its product portfolio for enabling multi-rate Ethernet transport and applications far beyond Data Center Interconnects. The new DSP ExaSPEED400-R focuses on 400ZR and OpenZR+ interoperable QSFP-DD applications, and achieves 20% less power consumption than its upper-compatible ExaSPEED400 for CFP2-DCO applications.
The new ExaSPEED400-R supports both OIF 400ZR and OpenZR+ MSA 100G-400G specification at the line side, and provides Ethernet transport with 8x25G-NRZ and 8x50G-PAM4 interfaces at the client side. It supports fully flexible Ethernet formats: 1x100GE, 2x100GE/1x200GE, 3x100GE, and 4x100GE/2x200GE/1x400GE.
“This is a very exciting development enabling the use of a low-power DSP in interoperable coherent QSFP-DD modules for an expansion of the application space by cloud network operations and service providers,” said Atul Srivastava, Co-chair of the OpenZR+ MSA Group.
At ECOC 2022, NTT Electronics will show a video demonstration of QSFP-DD module interoperability at 400G OpenZR+ including over 1000km straight fiber transmission, with the support of its QSFP-DD partners Fujitsu Optical Components Ltd., Molex LLC, and NEC Corporation.
Mogi Masahiro, President, Fujitsu Optical Components America Inc, commented as below. “For many years, from the inception of the coherent optical transmission technology, NTT Electronics and Fujitsu Optical Components (FOC) have established a successful partnership to bring the most advanced optical transceiver products to market. We are now very pleased that interoperable coherent transmission has been achieved successfully between FOC’s QSFP-DD optical transceiver, incorporating NTT Electronics’ new ExaSPEED400-R DSP chip, and multi-vendors’ QSFP-DD transceivers. Using FOC’s optical transceiver which enables transmission distance extension with low-power consumption, we are very pleased to be contributing to the ecosystem of interoperable coherent transceivers for data center and service provider networks.”
“Molex is focused on expanding the reach for data center interconnect beyond 120km, recognizing the industry need for significantly improved performance,” said Joseph Chon, director, Coherent Technology and Product Line Management, Molex Optoelectronics. “Collaborating with NTT Electronics and its module partners has accelerated the overall business opportunity for the interoperable QSFP-DD Interconnect Systems and we look forward to supporting evolving customer requirements in this space.”
“We have been developing and producing the state-of-art digital coherent transceivers for more than a decade.” said Akio Goto, General Manager of Photonic Device Development Department, NEC, “And now, as part of continuous collaborations to expand the digital coherent business with NTT Electronics, we have succeeded in developing QSFP-DD, competitive in the market, by using our technical assets and experience. We are accelerating their deployments for various markets.”
ExaSPEED400-R is now ramping up its production volume.
About NTT Electronics
NTT Electronics has been developing and commercializing optical communications devices since 1995. It has complete portfolio of optical and electronics products to cover the industry needs for 100G-and-beyond systems, ROADM components and FTTH networks. Since 2012 NTT Electronics has been delivering its flag-ship 100G coherent DSP that has been widely adopted in the industry. NTT Electronics is headquartered in Yokohama, Japan with offices in Milan, Italy, San Jose, CA, and Shenzhen, China. For more information, go to http://www.ntt-electronics.com/en/about/overview.html
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220915005082/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 12:31:00 CET | Press release
The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p
Lattice Wins 2025 Global Semiconductor Alliance Award6.12.2025 00:49:00 CET | Press release
‒ Named Most Respected Public Semiconductor Company Achieving $100 Million to $500 Million in Annual Sales ‒ Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced that it was selected as ‘Most Respected Public Semiconductor Company’ at the 2025 Global Semiconductor Alliance (GSA) Awards. The GSA awards recognize companies that have demonstrated excellence through their success, vision, strategy, and future opportunities in the industry as determined by votes from GSA members. “We are honored to be recognized by the Global Semiconductor Alliance and our peers as one of 2025’s most respected public semiconductor companies. This recognition reflects the dedication of the Lattice team and the trust of our customers, partners, suppliers, and investors. Looking ahead, we remain laser-focused on driving innovation and strengthening our role as the trusted low power programmable leader for semiconductor and system solutions,” said Ford Tamer, Chief Executive
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
